EANM 2025
SSTR-Targeting Theranostics in NETs and Beyond: Milestones and New Frontiers
Learn more about the development and emerging clinical role of investigational 177Lu-edotreotide in the treatment of neuroendocrine tumors (NETs), focusing on its scientific origins and current evidence supporting its use in gastroenteropancreatic NETs. Additionally, the session will explore future directions in SSTR-targeted therapies.
SYMPOSIUM HOST:
Prof. Ken Herrmann, M.D., MBA
Nuclear Medicine,
University Clinic Essen, Essen, Germany
Speakers
FROM CONCEPT TO CLINIC: THE ORIGINS OF 177LU-EDOTREOTIDE IN NETS
Prof. Vikas Prasad, M.D., PhD
Nuclear Medicine,
Mallinckrodt Institute of Radiology,
St. Louis, USA
TRANSLATING EVIDENCE INTO PRACTICE: THE ROLE OF 177LU-EDOTREOTIDE IN NETS
Dr. Rocío García-Carbonero, M.D., PhD
Medical Oncology,
University Hospital 12 de Octubre,
Madrid, Spain
EXPLORING THE FUTURE OF THE SSTR-TARGETING LANDSCAPE
Prof. Damian Wild, M.D., PhD
Nuclear Medicine,
University Hospital Basel,
Basel, Switzerland